A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2016
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 09 Feb 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 09 Feb 2016 Change in Treatment table: A Placebo cohort has been added to treatments as per ClinicalTrials.gov record.
- 02 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.